Allarity starts Phase 2 lung cancer trial

Allarity Therapeutics, Inc. reported that enrollment has opened for a new Phase 2 clinical trial.

(Moderate)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Allarity Therapeutics, Inc. reported that enrollment has opened for a new Phase 2 clinical trial. The study evaluates a combination of stenoparib and temozolomide to treat patients with recurrent small cell lung cancer.

The company released a press statement about this development, which is included as an exhibit to the report and incorporated by reference.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Allarity Therapeutics (ALLR) announce in this 8-K filing?

Allarity Therapeutics announced that enrollment has opened for a new Phase 2 clinical trial. The trial tests stenoparib combined with temozolomide in recurrent small cell lung cancer, and the company provided a detailed press release as an exhibit.

What is the focus of Allarity Therapeutics' new Phase 2 trial?

The Phase 2 trial focuses on treating recurrent small cell lung cancer using a combination of stenoparib and temozolomide. This study targets patients whose cancer has returned after prior treatment, aiming to evaluate safety and potential clinical benefit of the drug combination.

When did Allarity Therapeutics (ALLR) open enrollment for the new trial?

Allarity Therapeutics opened enrollment for the new Phase 2 clinical trial on February 3, 2026. This timing is noted as the date of the event in the report, and aligns with the press release included as an exhibit to the filing.

Which drugs are being evaluated in Allarity Therapeutics' Phase 2 lung cancer study?

The Phase 2 study evaluates a combination of stenoparib and temozolomide. Stenoparib is combined with the chemotherapy agent temozolomide to treat recurrent small cell lung cancer, and the trial aims to understand how this pairing performs in that patient group.

Where can investors find more details on Allarity Therapeutics' Phase 2 trial?

Investors can find more details in the press release filed as Exhibit 99.1 to the report. That press release, dated February 3, 2026, is incorporated by reference and should describe the trial design, objectives, and key scientific or clinical background.

Does the Allarity Therapeutics 8-K include any financial results or earnings data?

The 8-K centers on the opening of enrollment for a Phase 2 trial and does not present earnings data. It instead highlights a development in the company’s clinical pipeline, supported by a related press release attached as an exhibit to the report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 02/04/2026 - 08:00 AM EST

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) February 3, 2026

ALLARITY THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-41160		87-2147982
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

123 E Tarpon Ave,

Tarpon Springs, FL 34689

(Address of principal executive offices)

(401) 426-4664

(Registrant’s telephone number, including area code)

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		ALLR		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Matters.

On February 3, 2026, Allarity Therapeutics, Inc. (the “Company”) announced that enrollment has opened for its new Phase 2 clinical trial evaluating the combination of stenoparib and temozolomide for the treatment of recurrent small cell lung cancer. The Company’s press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
99.1		Press Release, dated February 3, 2026.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Allarity Therapeutics, Inc.

Date: February 4, 2026	By:	/s/ Thomas H. Jensen
		Thomas H. Jensen
		Chief Executive Officer

Source: View Original Filing on SEC EDGAR